As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: March 29, 2015
by Elizabeth Gough-Gordon for MPR:
Memory problems associated with Alzheimer’s disease may one day be reversed with targeted immunotherapy, according to a new study appearing in theJournal of Neuroscience.
Scientists from the University of Texas Medical Branch at Galveston had previously found that anti-tau oligomer immunotherapy reduced levels of toxic tau oligomers and reversed memory deficits in an animal model of Alzheimer’s disease.
In the current research of passive immunotherapy with tau oligomer-specific monoclonal antibody, the removal of tau oligomers also reversed memory deficits and accelerated plaque deposition in the brains of mice. Unlike other tau immunotherapy treatments, this one only targeted the toxic oligomer form of tau, leaving the normal tau to carry out typical functions.
However, amyloid beta oligomer levels were also reduced with the immunotherapy, which indicates that the effects of amyloid beta may also be dependent on the presence of toxic forms of tau.
These results support the targeting of tau oligomers with immunotherapy as a potential treatment for Alzheimer’s disease. The removal of tau oligomers with immunotherapy could also decrease the harmful effects of amyloid beta and mediate memory problems.
Thirty-six million people worldwide suffer from Alzheimer’s disease and dementia. In Canada, 25,000 new cases are diagnosed each year. Those sobering numbers have researchers around the globe racing to come up with new ways to...
he Food and Drug Administration issued new guides on drug development for neurological disorders. This sets the stage for possible treatments for Alzheimer’s. The disease-oriented development guide documents will provide details on how researchers...
For young adults with autosomal dominant Alzheimer’s disease (AD), molecular markers can identify changes associated with the disease before clinical onset, according to a study published online Feb. 12 in JAMA Neurology. Yakeel T. Quiroz, Ph.D., from Massachusetts...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.